STING1 and neoplasm: Several STING agonists have been tested or are currently under clinical trial due to their ability to boost immune response against tumor cells, while STING inhibitors have been proposed as a potential treatment against autoimmune disorders (Zhang et al., 2022b; Zhao et al., 2022).